Past year
All results
- All results
- Verbatim
Aug 21, 2024 · Similarly, a superior response rate was seen when the combination of bortezomib, thalidomide, and dexamethasone (VTd) was compared with thalidomide plus ...
May 17, 2024 · Bortezomib in the maintenance setting is well tolerated, efficacious, and can be continued without evidence of secondary malignancy until disease progression.
Missing: (Velcade | Show results with:(Velcade
Aug 21, 2024 · All transplant-eligible multiple myeloma patients should receive a triplet induction therapy (immunomodulatory agents, proteasome inhibitors, and dexamethasone) ...
Jan 8, 2024 · While it does not cure the disease, autologous stem cell transplant can lead to significant and prolonged responses in multiple myeloma. Transplant can be done ...
Missing: superior | Show results with:superior
Sep 3, 2024 · In this review, we examine the role of SAT in the current MM treatment landscape in the context of recent data on the efficacy of CAR-T therapy in this disease.
Jan 31, 2024 · Two recent studies comparing early versus late AHCT, have demonstrated that transplantation confers superior progression-free survival (PFS) in all patients and ...
May 6, 2024 · High-dose therapy (HDT) followed by an autologous stem cell transplantation (ASCT) is considered part of the standard of care for eligible patients with newly ...
Jul 25, 2024 · MRD-negativity at 12 months reduced the risk of progression; the treatment effect on MRD was correlated with the treatment effect on PFS.
Apr 1, 2024 · Superior response rates have been reported for thalidomide plus dexamethasone as compared with dexamethasone alone for induction therapy in patients with ...
Dec 30, 2023 · This review overviews the current recommendations for managing MGUS, SMM, MM, SP and NSMM and discusses practices in diagnosing and treating MM.
People also search for
